IRIS
IRIS Home | Critical Effect Search Results
Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the
RfD, RfC, oral slope factor, or inhalation unit risk.
Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with
organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see
Quick Check: Assessments in Development.
Search Filtered by: Critical Effect = "Urinary"
Number of records: 80
| Chemical Name | CASRN | Exposure Route | Critical Effect | RfD/RfC | RfD/RfC Value |
|---|---|---|---|---|---|
| Acetochlor | 34256-82-1 | Oral | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | RFD | 2 x 10 -2 mg/kg-day |
| Acetone | 67-64-1 | Oral | Nephropathy | RFD | 9 x 10 -1 mg/kg-day |
| Acifluorfen, sodium | 62476-59-9 | Oral | Mortality and kidney lesions | RFD | 1.3 x 10 -2 mg/kg-day |
| Allyl alcohol | 107-18-6 | Oral | Impaired renal function and increased liver and kidney weights | RFD | 5 x 10 -3 mg/kg-day |
| Barium and Compounds | 7440-39-3 | Oral | Nephropathy | RFD | 2 x 10 -1 mg/kg-day |
| Baythroid | 68359-37-5 | Oral | Decreased body weights in males, inflammatory foci in kidneys of females | RFD | 2.5 x 10 -2 mg/kg-day |
| Benzaldehyde | 100-52-7 | Oral | Forestomach lesions, kidney toxicity | RFD | 1 x 10 -1 mg/kg-day |
| Biphenyl | 92-52-4 | Oral | Renal papillary mineralization in male F344 rats | RFD | 5 x 10 -1 mg/kg-day |
| Bromate | 15541-45-4 | Oral | Renal effects: urothelial hyperplasia | RFD | 4 x 10 -3 mg/kg-day |
| Bromodichloromethane | 75-27-4 | Oral | Renal cytomegaly | RFD | 2 x 10 -2 mg/kg-day |
| Cadmium | 7440-43-9 | Oral | Significant proteinuria | RFD | 5 x 10 -4 mg/kg-day |
| Cadmium | 7440-43-9 | Oral | Significant proteinuria | RFD | 1 x 10 -3 mg/kg-day |
| Captafol | 2425-06-1 | Oral | Kidney and bladder toxicity | RFD | 2 x 10 -3 mg/kg-day |
| Carbaryl | 63-25-2 | Oral | Kidney and liver toxicity | RFD | 1 x 10 -1 mg/kg-day |
| Chlordecone (Kepone) | 143-50-0 | Oral | Renal lesions (glomerulosclerosis) in female Wistar rats | RFD | 3 x 10 -4 mg/kg-day |
| Chlorodifluoromethane | 75-45-6 | Inhalation | Increased kidney, adrenal and pituitary weights | RFC | 5 x 10 1 mg/m3 |
| Chlorothalonil | 1897-45-6 | Oral | Renal tubular epithelial vacuolation | RFD | 1.5 x 10 -2 mg/kg-day |
| Chlorpropham | 101-21-3 | Oral | Kidney, spleen, liver, and bone marrow toxicity | RFD | 2 x 10 -1 mg/kg-day |
| Copper cyanide | 544-92-3 | Oral | Decreased body and organ weights, histopathologic alterations in liver and kidney | RFD | 5 x 10 -3 mg/kg-day |
| Cumene | 98-82-8 | Inhalation | Increased kidney weights in female rats and adrenal weights in male and female rats | RFC | 4 x 10 -1 mg/m3 |
| Cumene | 98-82-8 | Oral | Increased average kidney weight in female rats | RFD | 1 x 10 -1 mg/kg-day |
| Dacthal | 1861-32-1 | Oral | Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females | RFD | 1 x 10 -2 mg/kg-day |
| Dalapon, sodium salt | 75-99-0 | Oral | Increased kidney body weight ratio | RFD | 3 x 10 -2 mg/kg-day |
| Di(2-ethylhexyl)adipate | 103-23-1 | Oral | Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size | RFD | 6 x 10 -1 mg/kg-day |
| cis-1,2-Dichloroethylene | 156-59-2 | Oral | Increased relative kidney weight in male rats | RFD | 2 x 10 -3 mg/kg-day |
| 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Oral | Hematologic, hepatic and renal toxicity | RFD | 1 x 10 -2 mg/kg-day |
| 2,3-Dichloropropanol | 616-23-9 | Oral | Myocardial degeneration, hepatotoxicity and nephrotoxicity | RFD | 3 x 10 -3 mg/kg-day |
| Dimethyl terephthalate (DMT) | 120-61-6 | Oral | Chronic kidney inflammation | RFD | 1 x 10 -1 mg/kg-day |
| 2,6-Dimethylphenol | 576-26-1 | Oral | Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) | RFD | 6 x 10 -4 mg/kg-day |
| 3,4-Dimethylphenol | 95-65-8 | Oral | Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen | RFD | 1 x 10 -3 mg/kg-day |
| 1,4-Dioxane | 123-91-1 | Oral | Liver and kidney toxicity | RFD | 3 x 10 -2 mg/kg-day |
| Diphenylamine | 122-39-4 | Oral | Decreased body weight gain, and increased liver and kidney weights | RFD | 2.5 x 10 -2 mg/kg-day |
| Endosulfan | 115-29-7 | Oral | Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males | RFD | 6 x 10 -3 mg/kg-day |
| Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Oral | Increased absolute kidney weight in female rats | RFD | 1 mg/kg-day |
| Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Inhalation | Increased absolute kidney weight in female rats | RFC | 4 x 10 1 mg/m3 |
| Ethylbenzene | 100-41-4 | Oral | Liver and kidney toxicity | RFD | 1 x 10 -1 mg/kg-day |
| Ethylene glycol | 107-21-1 | Oral | Kidney toxicity | RFD | 2 mg/kg-day |
| Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | Oral | Kidney damage and reduced lifespan | RFD | 3 mg/kg-day |
| Express | 101200-48-0 | Oral | Elevated serum bilirubin and AST levels, increased urinary volume | RFD | 8 x 10 -3 mg/kg-day |
| Fluoranthene | 206-44-0 | Oral | Nephropathy, increased liver weights, hematological alterations, and clinical effects | RFD | 4 x 10 -2 mg/kg-day |
| Fluridone | 59756-60-4 | Oral | Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights | RFD | 8 x 10 -2 mg/kg-day |
| Formaldehyde | 50-00-0 | Oral | Reduced weight gain, histopathology in rats | RFD | 2 x 10 -1 mg/kg-day |
| Glufosinate-ammonium | 77182-82-2 | Oral | Increased absolute and relative kidney weights in males | RFD | 4 x 10 -4 mg/kg-day |
| Glycidaldehyde | 765-34-4 | Oral | Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects | RFD | 4 x 10 -4 mg/kg-day |
| Glyphosate | 1071-83-6 | Oral | Increased incidence of renal tubular dilation in F3b offspring | RFD | 1 x 10 -1 mg/kg-day |
| Haloxyfop-methyl | 69806-40-2 | Oral | Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation | RFD | 5 x 10 -5 mg/kg-day |
| gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Oral | Liver and kidney toxicity | RFD | 3 x 10 -4 mg/kg-day |
| Hexachloroethane | 67-72-1 | Oral | Atrophy and degeneration of renal tubules | RFD | 7 x 10 -4 mg/kg-day |
| Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Kidney medullary papillary necrosis in F344 rats | RFD | 1 x 10 -2 mg/kg-day |
| Isophorone | 78-59-1 | Oral | Kidney pathology | RFD | 2 x 10 -1 mg/kg-day |
| Isoxaben | 82558-50-7 | Oral | Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight | RFD | 5 x 10 -2 mg/kg-day |
| Maleic anhydride | 108-31-6 | Oral | Renal lesions | RFD | 1 x 10 -1 mg/kg-day |
| Maleic hydrazide | 123-33-1 | Oral | Renal dysfunction | RFD | 5 x 10 -1 mg/kg-day |
| Mercuric chloride (HgCl2) | 7487-94-7 | Oral | Autoimmune effects (autoimmune glomerulonephritis) | RFD | 3 x 10 -4 mg/kg-day |
| Methomyl | 16752-77-5 | Oral | Kidney and spleen pathology | RFD | 2.5 x 10 -2 mg/kg-day |
| Methyl tert-butyl ether (MTBE) | 1634-04-4 | Inhalation | Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) | RFC | 3 mg/m3 |
| 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Oral | Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights | RFD | 1 x 10 -2 mg/kg-day |
| 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | Oral | Increased absolute and relative kidney weights | RFD | 1 x 10 -3 mg/kg-day |
| 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Oral | Kidney and liver toxicity | RFD | 5 x 10 -4 mg/kg-day |
| Metribuzin | 21087-64-9 | Oral | Liver and kidney effects, decreased body weight, mortality | RFD | 2.5 x 10 -2 mg/kg-day |
| Molybdenum | 7439-98-7 | Oral | Increased uric acid levels | RFD | 5 x 10 -3 mg/kg-day |
| Oryzalin | 19044-88-3 | Oral | Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights | RFD | 5 x 10 -2 mg/kg-day |
| Pentachlorobenzene | 608-93-5 | Oral | Liver and kidney toxicity | RFD | 8 x 10 -4 mg/kg-day |
| Phenylmercuric acetate | 62-38-4 | Oral | Renal damage | RFD | 8 x 10 -5 mg/kg-day |
| Phthalic anhydride | 85-44-9 | Oral | Lung and kidney histopathology | RFD | 2 mg/kg-day |
| Prometryn | 7287-19-6 | Oral | Liver and kidney degeneration and bone marrow atrophy | RFD | 4 x 10 -3 mg/kg-day |
| Propargyl alcohol | 107-19-7 | Oral | Renal and hepatotoxicity | RFD | 2 x 10 -3 mg/kg-day |
| Pyrene | 129-00-0 | Oral | Kidney effects (renal tubular pathology, decreased kidney weights) | RFD | 3 x 10 -2 mg/kg-day |
| 1,2,4,5-Tetrachlorobenzene | 95-94-3 | Oral | Kidney lesions | RFD | 3 x 10 -4 mg/kg-day |
| 1,1,1,2-Tetrachloroethane | 630-20-6 | Oral | Mineralization of the kidneys in males, hepatic clear cell change in females | RFD | 3 x 10 -2 mg/kg-day |
| Tetrachlorovinphos | 961-11-5 | Oral | Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition | RFD | 3 x 10 -2 mg/kg-day |
| Thiobencarb | 28249-77-6 | Oral | Decrease in body weight, increase in BUN | RFD | 1 x 10 -2 mg/kg-day |
| Toluene | 108-88-3 | Oral | Increased kidney weight | RFD | 8 x 10 -2 mg/kg-day |
| 2,4,5-Trichlorophenol | 95-95-4 | Oral | Liver and kidney pathology | RFD | 1 x 10 -1 mg/kg-day |
| 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | Oral | Increased urinary coproporphyrins | RFD | 1 x 10 -2 mg/kg-day |
| 1,1,2-Trichloropropane | 598-77-6 | Oral | Mild lesions in liver, kidney and thyroid | RFD | 5 x 10 -3 mg/kg-day |
| Uranium, soluble salts | Various | Oral | Initial body weight loss moderate nephrotoxicity | RFD | 3 x 10 -3 mg/kg-day |
| Vinclozolin | 50471-44-8 | Oral | Organ weight changes (adrenal and kidney) | RFD | 2.5 x 10 -2 mg/kg-day |
| tert-Butyl Alcohol (tBA) | 75-65-0 | Oral | Increased severity of nephropathy | RFD | 4 x 10 -1 mg/kg-day |
| tert-Butyl Alcohol (tBA) | 75-65-0 | Inhalation | Increased severity of nephropathy | RFC | 5 mg/m3 |